Every 10-Q that Gt Biopharma Inc (GTBP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GTBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GTBP filings page.
GT Biopharma, Inc. reported a Q2 2026 net loss of $4.5 million, and a six‑month net loss of $7.4 million, with no revenue. Operating expenses for the six months rose to $7.4 million, driven mainly by a sharp increase in selling, general and administrative costs, while research and development spending was roughly flat year over year.
Cash and cash equivalents were $4.96 million at June 30 2026, total assets were $5.8 million, and working capital was $3.6 million. Net cash used in operations was $6.7 million for the six months, partially offset by $4.9 million of financing inflows from warrant exercises and issuances of Series L preferred stock. Management disclosed substantial doubt about the company’s ability to continue as a going concern within one year without additional financing.
The company continues as a clinical‑stage immuno‑oncology developer advancing its TriKE® and Dual Targeting TriKE® platforms. INDs for lead candidates GTB‑3650 (relapsed/refractory AML and high‑risk MDS) and GTB‑5550 (B7‑H3–positive solid tumors) have been cleared by the FDA, with GTB‑3650 having four cohorts enrolled and the first GTB‑5550 patient dosed in May 2026. However, GT Biopharma remains out of compliance with Nasdaq’s $1.00 minimum bid price rule (with an extension to November 16 2026) and continues to report a previously identified material weakness in internal control over accounting for complex financial instruments.
GT Biopharma, Inc. filed an amended Q2 2025 report restating its June 30, 2025 interim financials after reclassifying Greenshoe Rights tied to its May 2025 Series L preferred financing as a liability under ASC 480. This created a Greenshoe Rights liability of $28.736 million and turned stockholders’ equity into a $25.875 million deficit.
The company reported no revenue and a net loss of $30.2 million for the quarter and $30.9 million for the first half of 2025, driven largely by the Greenshoe Rights loss recognition. Cash and restricted cash totaled $5.321 million, while current liabilities reached $31.043 million.
Management states there is substantial doubt about GT Biopharma’s ability to continue as a going concern, citing ongoing losses and limited liquidity. To bolster funding, the company completed a Series L 10% Convertible Preferred Stock and warrant financing with net proceeds of $5.441 million and set up a $20 million committed equity facility, while also curing a prior Nasdaq stockholders’ equity deficiency.
GT Biopharma, Inc. filed an amended quarterly report for the nine months ended September 30, 2025 to restate its financial statements after identifying material errors in accounting for Greenshoe Rights linked to its Series L preferred stock. The Greenshoe Rights were reclassified as a liability under ASC 480 and marked to fair value, producing an $11.4 million gain in Q3 from a change in fair value and a $28.7 million initial loss, with $17.3 million later reclassified to equity.
The company remains a clinical-stage biopharma with no product revenue and reported a net loss of about $22.6 million for the nine-month period, despite Q3 net income of $8.3 million driven by non-cash fair value movements. Cash and cash equivalents were $2.5 million and total assets $4.3 million as of September 30, 2025, with positive stockholders’ equity of $3.0 million.
Management and the auditor concluded there is substantial doubt about GT Biopharma’s ability to continue as a going concern within one year without additional financing, given ongoing operating losses and approximately $8.9 million of cash used in operating activities in the first nine months of 2025. The restatement also led the company to deem its disclosure controls and procedures ineffective as of September 30, 2025.
GT Biopharma, Inc. (GTBP) filed its Q3 2025 10‑Q, reporting no revenue and a narrower net loss. The company lost $3.1 million in Q3, compared with $3.4 million a year ago, and $5.3 million for the nine months, versus $9.4 million in the prior-year period. Operating expenses fell year over year as research and development was $0.6 million and selling, general and administrative was $2.7 million in Q3. Other income was $0.3 million in Q3, helped by warrant liability revaluation.
Cash and cash equivalents were $2.53 million, total assets $4.32 million, and current liabilities $1.32 million as of September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern. Financing actions included issuing Series L 10% Convertible Preferred Stock (with dividends declared of $229,000) and establishing a committed equity facility of up to $20 million. Common shares outstanding were 6,051,874 as of September 30, 2025, and 10,636,135 as of November 6, 2025.